Analysts have been eager to weigh in on the Healthcare sector with new ratings on SCYNEXIS (SCYX – Research Report) and Kymera Therapeutics (KYMR – Research Report).
SCYNEXIS (SCYX)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on SCYNEXIS, with a price target of $7.50. The company’s shares closed last Tuesday at $2.21.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SCYNEXIS with a $7.50 average price target.
See the top stocks recommended by analysts >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SCYX:
